| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acknowledgements
|
|
|
|
31 |
S7 |
p. vii
|
artikel
|
| 2 |
Editorial Board
|
|
|
|
31 |
S7 |
p. i
|
artikel
|
| 3 |
ESMO
|
|
|
|
31 |
S7 |
p. v
|
artikel
|
| 4 |
ESMO Immuno-Oncology Virtual Congress 2020 Officers
|
|
|
|
31 |
S7 |
p. vi
|
artikel
|
| 5 |
LBA1 First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743
|
Scherpereel, A.
|
|
|
31 |
S7 |
p. S1441
|
artikel
|
| 6 |
65MO A phase I clinical trial on intratumoural (IT) administration of ipilimumab (IPI) plus nivolumab (NIVO) followed by intracavitary (IC) administration of nivolumab in patients with recurrent glioblastoma
|
Schwarze, J.K.
|
|
|
31 |
S7 |
p. S1443
|
artikel
|
| 7 |
33MO A phase I study of SHC014748M capsules in patients with relapsed or refractory indolent B-cell malignancies
|
Xu, W.
|
|
|
31 |
S7 |
p. S1428
|
artikel
|
| 8 |
64MO A phase (ph) II, multi-center study of the safety and efficacy of tebentafusp (tebe) (IMCgp100) in patients (pts) with metastatic uveal melanoma (mUM)
|
Sacco, J.J.
|
|
|
31 |
S7 |
p. S1442-S1443
|
artikel
|
| 9 |
62MO A randomised, controlled, multicenter phase II trial of camrelizumab combined with albumin-bound paclitaxel and cisplatin as neoadjuvant treatment in locally advanced NSCLC
|
Lei, J.
|
|
|
31 |
S7 |
p. S1441-S1442
|
artikel
|
| 10 |
24MO Randomized, multicenter, open-label trial of autologous cytokine-induced killer cell immunotherapy plus chemotherapy for squamous non-small cell lung cancer
|
Liu, L.
|
|
|
31 |
S7 |
p. S1425
|
artikel
|
| 11 |
63MO TG4001 therapeutic vaccination combined with PD-L1 blocker avelumab remodels the tumor microenvironement (TME) and drives antitumor responses in human papillomavirus (HPV)+ malignancies
|
Le Tourneau, C.
|
|
|
31 |
S7 |
p. S1442
|
artikel
|
| 12 |
Notice and Disclaimer
|
|
|
|
31 |
S7 |
p. iii
|
artikel
|
| 13 |
1O Clinical outcomes in post-operative ctDNA-positive muscle-invasive urothelial carcinoma (MIUC) patients after atezolizumab adjuvant therapy
|
Powles, T.B.
|
|
|
31 |
S7 |
p. S1417
|
artikel
|
| 14 |
29P ALLELE study: A multicenter, open label, phase III study of tabelecleucel for solid organ or allogeneic hematopoietic cell transplant subjects with Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) after failure of rituximab or rituximab and chemotherapy
|
Worel, N.
|
|
|
31 |
S7 |
p. S1426-S1427
|
artikel
|
| 15 |
87P An augmented exome/transcriptome-based platform for precision cancer therapy selection, clinical trial matching, and oncology research applications, enabling next-generation composite biomarkers by combining tumour and immune features
|
Power, R.
|
|
|
31 |
S7 |
p. S1452
|
artikel
|
| 16 |
71P A phase II study of ADU-S100 in combination with pembrolizumab in adult patients with PD-L1+ recurrent or metastatic HNSCC: Preliminary safety, efficacy and PK/PD results
|
Zandberg, D.P.
|
|
|
31 |
S7 |
p. S1446-S1447
|
artikel
|
| 17 |
3P Association between inflammation index and nutritional status and the effectiveness of immunotherapy in NSCLC treatment
|
Tolu, S.
|
|
|
31 |
S7 |
p. S1418
|
artikel
|
| 18 |
78P Cancer immunotherapy: Rejuvenation of anti-cancer response by immune checkpoint blockade using novel multifunctional nanoparticle to block CTLA-4 and eliminate ICER
|
Bodor, J.
|
|
|
31 |
S7 |
p. S1449
|
artikel
|
| 19 |
41P Cardiotoxicity of immune checkpoint inhibitors: A meta-analysis of randomized clinical trials
|
Agostinetto, E.
|
|
|
31 |
S7 |
p. S1432
|
artikel
|
| 20 |
26P Cellulose beads prepared in deep eutectic solvent function as carrier and cytoprotective encapsulation matrix for CAR-T cells in T-cell therapy against glioblastoma cells
|
Vuoti, S.
|
|
|
31 |
S7 |
p. S1425-S1426
|
artikel
|
| 21 |
92P Characterising the role of HDAC6 in the control of human macrophage IL-10 production
|
Beer, P.A.
|
|
|
31 |
S7 |
p. S1454
|
artikel
|
| 22 |
21P Characteristics of the lymphocytic infiltrate in breast cancer
|
Ben Kridis, W.
|
|
|
31 |
S7 |
p. S1424
|
artikel
|
| 23 |
9P Circulating tumour cells (CTCs) count and PD-L1 expression in untreated extensive small cell lung cancer patients treated in the REACTION trial, a phase II study of etoposide and cis/carboplatin with or without pembrolizumab (NCT02580994)
|
Menis, J.
|
|
|
31 |
S7 |
p. S1420
|
artikel
|
| 24 |
93P CXCL8 and CCL2 production in circulating neutrophils in endometrial cancer
|
Abakumova, T.
|
|
|
31 |
S7 |
p. S1454
|
artikel
|
| 25 |
83P Development of steroid-refractory graft-versus-host disease in a patient with Hodgkin lymphoma treated with nivolumab before allogeneic hematopoietic stem cells transplantation
|
Anastasiya, B.
|
|
|
31 |
S7 |
p. S1451
|
artikel
|
| 26 |
52P Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with non small-cell lung carcinoma (NSCLC): INTEPI, a multicentric retrospective study
|
Bilger, G.
|
|
|
31 |
S7 |
p. S1436
|
artikel
|
| 27 |
49P Discontinuation of immune checkpoint inhibitors in patients with relapsed and refractory classical Hodgkin lymphoma
|
Fedorova, L.
|
|
|
31 |
S7 |
p. S1435-S1436
|
artikel
|
| 28 |
89P Dissecting tumour-immune interactions in mesothelioma for identifying responders to immune checkpoint blockade
|
Addala, V.
|
|
|
31 |
S7 |
p. S1453
|
artikel
|
| 29 |
22P Dynamics of indicators of the immune status in patients with metastatic solid tumours on the background of stereotactic ablative radiation therapy
|
Zozulya, A.
|
|
|
31 |
S7 |
p. S1424
|
artikel
|
| 30 |
17P Effects of tumour mutation burden on the antigen presentation pathway
|
Garcia-Rivera, E.M.
|
|
|
31 |
S7 |
p. S1422-S1423
|
artikel
|
| 31 |
40P Efficacy and safety of immune checkpoint inhibitors in previously treated metastatic non-small cell lung cancer
|
Cunha, R.
|
|
|
31 |
S7 |
p. S1432
|
artikel
|
| 32 |
56P Efficacy and safety of nivolumab (Nivo) in recurrent and/or metastatic platinum-refractory squamous cell carcinoma of head and neck (R/M SCCHN): A real-world data study
|
Castillo, J.J. Soto
|
|
|
31 |
S7 |
p. S1438
|
artikel
|
| 33 |
75P Efficacy and updated safety results from pivotal phase II trial 201 of naxitamab (Hu3F8): A humanized GD2-targeted immunotherapy for the treatment of refractory/relapsed (R/R) high-risk (HR) neuroblastoma (NB)
|
Mora, J.
|
|
|
31 |
S7 |
p. S1448
|
artikel
|
| 34 |
68P Evaluation of flat dosing for nivolumab (NIVO) + ipilimumab (IPI) in first-line (1L) unresectable malignant pleural mesothelioma (MPM): CheckMate 743 (CM 743)
|
Tsao, A.S.
|
|
|
31 |
S7 |
p. S1445
|
artikel
|
| 35 |
46P [18F]2-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18FDG-PET/CT) in patients treated with immune checkpoint inhibitors (ICI) for microsatellite instability-high metastatic colorectal cancer (MSI mCRC)
|
Pudlarz, T.
|
|
|
31 |
S7 |
p. S1434
|
artikel
|
| 36 |
37P First-line BRAF/MEK-inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: A propensity-matched survival analysis
|
Breeschoten, J.V.
|
|
|
31 |
S7 |
p. S1431
|
artikel
|
| 37 |
73P αGalCer/antibody complex targeting EGFR-tumor-associated iNKT to restore the immune response
|
Dubreuil, D.
|
|
|
31 |
S7 |
p. S1447-S1448
|
artikel
|
| 38 |
90P Gastro-sphere effects on Th17/Treg diagram: Help or hindrance?
|
Rezalotfi, A.
|
|
|
31 |
S7 |
p. S1453
|
artikel
|
| 39 |
10P Genomic profiles of CD47 in breast tumours predict outcome and are associated with immune activation and enrichment of pro-tumoral macrophage markers
|
Ocaña, A.
|
|
|
31 |
S7 |
p. S1420
|
artikel
|
| 40 |
86P HEIH: A novel immunomodulatory LncRNA tweaking NK cells and TME in triple-negative breast cancer (TNBC) patients
|
Nafea, H.M.
|
|
|
31 |
S7 |
p. S1452
|
artikel
|
| 41 |
28P Helping the killers: Innovative cancer immunotherapy harnessing quasi-universal tumour antigen-specific CD4 T cells
|
Saillard, M.
|
|
|
31 |
S7 |
p. S1426
|
artikel
|
| 42 |
14P High CMTM6 and PD-L1 co-expression predict metastasis and poor prognosis in oesophageal squamous cell carcinoma
|
Luo, Y.
|
|
|
31 |
S7 |
p. S1422
|
artikel
|
| 43 |
76P Highly potent fully human anti-VISTA antibodies efficiently abrogate the interaction of this new target checkpoint inhibitor to its different putative receptors at different pH
|
Iadonato, S.
|
|
|
31 |
S7 |
p. S1448-S1449
|
artikel
|
| 44 |
88P Identification of prognostic radio-immune-genetic profiles in patients affected by glioblastoma
|
Mazzaschi, G.
|
|
|
31 |
S7 |
p. S1453
|
artikel
|
| 45 |
4P IgM-rheumatoid factor as a novel biomarker for a reduced survival in anti-PD-1 treated NSCLC patients through the decrease of CD137+ T-cells
|
Ugolini, A.
|
|
|
31 |
S7 |
p. S1418
|
artikel
|
| 46 |
8P Immune cell subsets in peripheral blood are associated with primary resistance to immunotherapy as frontline treatment in NSCLC
|
Arasanz, H.
|
|
|
31 |
S7 |
p. S1419-S1420
|
artikel
|
| 47 |
61P Immune check point inhibitors (ICIs) in cancer therapy: An experience from a resource poor and developing country
|
Naseer, M.
|
|
|
31 |
S7 |
p. S1440
|
artikel
|
| 48 |
95P Immune infiltrate in malignant tumors treated with nivolumab and/or ipilimumab
|
Joehrens, K.
|
|
|
31 |
S7 |
p. S1455
|
artikel
|
| 49 |
45P Immune-related adverse events: Spectrum and clinical features in the real world
|
Vieira, I.M.
|
|
|
31 |
S7 |
p. S1434
|
artikel
|
| 50 |
54P Impact of comorbidity and venous thromboembolism on outcome in real-life non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibition (ICI)
|
Bjoernhart, B.
|
|
|
31 |
S7 |
p. S1437
|
artikel
|
| 51 |
48P Impact of 12 months of immunotherapy for metastatic cancer patients on oncology workload
|
Andreotti, V.J.
|
|
|
31 |
S7 |
p. S1435
|
artikel
|
| 52 |
25P Improving efficacy and reducing toxicity of anti-PD-L1 treatment: T-cells as delivery vehicles for anti-PD-L1 blocking nanobodies
|
Petit, P-F.
|
|
|
31 |
S7 |
p. S1425
|
artikel
|
| 53 |
18P Influence of local immunity on the prognosis of gastric cancer
|
Khakimova, G.
|
|
|
31 |
S7 |
p. S1423
|
artikel
|
| 54 |
31P Integrated safety analysis of anti-programmed cell death-1 (PD-1) antibody penpulimab in advanced solid tumour or lymphoma
|
Xu, N.
|
|
|
31 |
S7 |
p. S1428-S1429
|
artikel
|
| 55 |
101P Knocking down of cystathionine-γ-lyase (CSE) in breast cancer alters PD-L1 expression pattern through tuning CCAT1/let-7a ceRNAs circuit
|
Selem, N.A.
|
|
|
31 |
S7 |
p. S1458
|
artikel
|
| 56 |
32P Low immunogenicity and favorable safety seen with novel regimen of tremelimumab (T) plus durvalumab (D) in patients (pts) with unresectable hepatocellular carcinoma (uHCC)
|
Kelley, R.K.
|
|
|
31 |
S7 |
p. S1429
|
artikel
|
| 57 |
98P Low prognostic nutritional index is independently associated with poorer survival in patients receiving immune checkpoint inhibitors
|
Guven, D.C.
|
|
|
31 |
S7 |
p. S1457
|
artikel
|
| 58 |
2P Lung immune prognostic index (LIPI) can identify the fast-progressor to immune checkpoints inhibitors (ICI) in microsatellite instability (MSI) or mismatch repair deficient (dMMR) tumours
|
Auclin, E.
|
|
|
31 |
S7 |
p. S1418
|
artikel
|
| 59 |
91P Macrophage-lineage transcriptome networking reveals SMAD3 as a novel regulator for cancer-associated fibroblasts formation in NSCLC
|
Tang, P.C.T.
|
|
|
31 |
S7 |
p. S1454
|
artikel
|
| 60 |
27P Methodology for identification of clinically relevant targets for TCR-immunotherapy in hepatocellular carcinoma
|
Maravelia, P.
|
|
|
31 |
S7 |
p. S1426
|
artikel
|
| 61 |
85P MiRNAome deregulation can contribute to overexpression of immune checkpoints: An epigenetic mechanism of checkpoint inhibitor therapy failure
|
Halytskiy, V.
|
|
|
31 |
S7 |
p. S1452
|
artikel
|
| 62 |
81P Monalizumab in combination with cetuximab post platinum and anti-PD-(L)1 in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Updated results from a phase II trial
|
Fayette, J.
|
|
|
31 |
S7 |
p. S1450
|
artikel
|
| 63 |
55P MOREL: Multicenter observational study on treatment and PD-L1 testing in patients (pts) with newly diagnosed stage IV NSCLC in Spain
|
Rubio-Viqueira, B.
|
|
|
31 |
S7 |
p. S1437-S1438
|
artikel
|
| 64 |
96P Neutrophil-specific single-cell RNA-sequencing discovers a novel smad3-dependent immunosuppressor PRDM2 for promoting NSCLC
|
Chung, J.
|
|
|
31 |
S7 |
p. S1455
|
artikel
|
| 65 |
94P New marker of tumour-associated macrophages IL-35 is negatively associated with lymphatic metastasis in colorectal cancer
|
Kazakova, E.O.
|
|
|
31 |
S7 |
p. S1455
|
artikel
|
| 66 |
82P Novel analysis of F. nucleatum subspecies in human CRC tissue and engineering of therapeutic F. nucleatum phage
|
Ninio-Many, L.
|
|
|
31 |
S7 |
p. S1450
|
artikel
|
| 67 |
43P Ocular adverse events due to PD-1 and PD-L1 checkpoint inhibitors: A retrospective review of FDA adverse events reporting system (FAERS)
|
Sahu, Y.
|
|
|
31 |
S7 |
p. S1433
|
artikel
|
| 68 |
80P Oncolytic adenovirus type 3 coding for CD40L facilitates dendritic cell therapy of prostate cancer in humanized mice and patient samples
|
Basnet, S.
|
|
|
31 |
S7 |
p. S1449-S1450
|
artikel
|
| 69 |
69P Outcomes with durvalumab and savolitinib in metastatic papillary renal cancer (mPRC) according to international metastatic renal cell carcinoma database consortium (IMDC) risk groups
|
Choy, J.
|
|
|
31 |
S7 |
p. S1446
|
artikel
|
| 70 |
34P Patient characteristics and treatment patterns in advanced renal cell carcinoma (aRCC): Following introduction of new therapies
|
Zakharia, Y.
|
|
|
31 |
S7 |
p. S1429-S1430
|
artikel
|
| 71 |
100P Patient-derived tissue cultures of esophagogastric-junction cancer (EGJC) and gastric cancer (GC): An ex vivo model to study individual response of immunotherapy
|
Körfer, J.
|
|
|
31 |
S7 |
p. S1457
|
artikel
|
| 72 |
13P PD-L1 prevalence in advanced urothelial carcinoma by demographic and clinical characteristics
|
Powles, T.B.
|
|
|
31 |
S7 |
p. S1421-S1422
|
artikel
|
| 73 |
16P PD-1/PD-L1 expression in uveal melanoma: Prognostic significance with tumour-infiltrating lymphocytes and clinicopathological parameters
|
Singh, L.
|
|
|
31 |
S7 |
p. S1422
|
artikel
|
| 74 |
7P Peripheral blood-based biomarkers of prognosis and treatment response in patients with non-small cell lung cancer treated with PD-1 inhibitors
|
Tourkantonis, I.
|
|
|
31 |
S7 |
p. S1419
|
artikel
|
| 75 |
74P Pivotal trial 201 data on outpatient administration of naxitamab (Hu3F8), a humanized GD2 targeted immunotherapy for the treatment of refractory/relapsed (R/R) high-risk (HR) neuroblastoma (NB)
|
Morgenstern, D.A.
|
|
|
31 |
S7 |
p. S1448
|
artikel
|
| 76 |
42P Pleural effusion is a negative prognostic factor for immunotherapy in non small cell lung cancer (NSCLC): The PLUIE study
|
Epaillard, N.
|
|
|
31 |
S7 |
p. S1433
|
artikel
|
| 77 |
38P Predicting objective response rate (ORR) in immune checkpoint inhibitor (ICI) therapies with machine learning (ML) by combining clinical and patient-reported data
|
Iivanainen, S.M.E.
|
|
|
31 |
S7 |
p. S1431
|
artikel
|
| 78 |
36P Progression-free survival as a surrogate for overall survival in trials of immune checkpoint inhibitors in pan cancer evaluated by RECIST 1.1
|
Lin, L.
|
|
|
31 |
S7 |
p. S1430
|
artikel
|
| 79 |
20P Quantitative whole slide assessment of CD8+ tumour-infiltrating lymphocytes in small cell esophageal carcinoma in relation to clinical outcome
|
Zhang, Z.
|
|
|
31 |
S7 |
p. S1423-S1424
|
artikel
|
| 80 |
47P Radiological patterns of tumour progression in patients treated with a combination of immune checkpoint blockers and antiangiogenic drugs
|
Guiard, E.
|
|
|
31 |
S7 |
p. S1435
|
artikel
|
| 81 |
59P Real-world data of immunotherapy in patients over 65 years old with lung cancer
|
Nuñez-Garcia, B.
|
|
|
31 |
S7 |
p. S1439
|
artikel
|
| 82 |
58P Real-world data of incidence of immune related toxicities with single agent immuno oncology drugs at a single center
|
Chandra, G. Sharat
|
|
|
31 |
S7 |
p. S1439
|
artikel
|
| 83 |
60P Real-world experience of immunotherapy in elderly cancer patients in a UK cancer centre
|
Mirza, S.
|
|
|
31 |
S7 |
p. S1439-S1440
|
artikel
|
| 84 |
6P Role of inflammatory cytokines in distant metastasis of non-small cell lung cancer
|
Savelieva, O.E.
|
|
|
31 |
S7 |
p. S1419
|
artikel
|
| 85 |
51P Shortcomings of immuno oncology (IO) agents application into real-world practise due to financial constraints in a resource constrained setting
|
Chandra, G. Sharat
|
|
|
31 |
S7 |
p. S1436
|
artikel
|
| 86 |
72P Single-cell transcriptomics identifies distinct PD-1 blockade resistance landscapes of tumour immune microenvironment among skin cancer subtypes
|
Li, A.
|
|
|
31 |
S7 |
p. S1447
|
artikel
|
| 87 |
79P Statins and immunotherapy: Togetherness makes strength - the potential effect of statins on immunotherapy for NSCLC
|
Filetti, M.
|
|
|
31 |
S7 |
p. S1449
|
artikel
|
| 88 |
53P Studying autoimmune diseases with thymic epithelial tumors (TET): Real-world insight from RYTHMIC
|
Benitez, J.C.
|
|
|
31 |
S7 |
p. S1437
|
artikel
|
| 89 |
67P Survival of responders to nivolumab (NIVO) + ipilimumab (IPI) as first-line treatment for advanced NSCLC in CheckMate 227, part 1
|
Brahmer, J.R.
|
|
|
31 |
S7 |
p. S1444-S1445
|
artikel
|
| 90 |
103P Temporospatial heterogeneity in metastatic colorectal cancer (mCRC)
|
Fountzilas, C.
|
|
|
31 |
S7 |
p. S1458
|
artikel
|
| 91 |
99P The association between antibiotic use and survival in renal cell carcinoma patients treated with nivolumab: A multi-center study
|
Guven, D.C.
|
|
|
31 |
S7 |
p. S1457
|
artikel
|
| 92 |
12P The correlation between non-coding RNA and response rate to immune-checkpoint inhibitors
|
Shek, D.
|
|
|
31 |
S7 |
p. S1421
|
artikel
|
| 93 |
57P The efficacy and safety of pembrolizumab in advanced cervical cancer: A real-world treatment study
|
Browne, I.
|
|
|
31 |
S7 |
p. S1438-S1439
|
artikel
|
| 94 |
44P The hematologic toxicities of chemo-immunotherapy compared to chemotherapy alone: A systematic review and meta-analysis
|
Eiger, D.
|
|
|
31 |
S7 |
p. S1433-S1434
|
artikel
|
| 95 |
39P The lung immune prognostic index (LIPI) as prognostic factor in solid tumours: The experience of a community hospital
|
Vitorino, M.
|
|
|
31 |
S7 |
p. S1431-S1432
|
artikel
|
| 96 |
66P Tislelizumab plus chemotherapy as first-line treatment for lung cancer in Chinese patients
|
Wang, Z.
|
|
|
31 |
S7 |
p. S1444
|
artikel
|
| 97 |
102P TNFa and IL-2 armed adenovirus promotes abscopal effect in mice treated with anti-PD-1 immunotherapy
|
Quixabeira, D.C.A.
|
|
|
31 |
S7 |
p. S1458
|
artikel
|
| 98 |
35P Toxicity and safety of novel immuno-oncology (IO) treatments after prior immune checkpoint inhibitors (ICIs) exposure
|
Valdivia, A.A.
|
|
|
31 |
S7 |
p. S1430
|
artikel
|
| 99 |
70P Treatment patterns and overall survival (OS) in patients with advanced BRAF mutant (mt) melanoma treated with immunotherapy and targeted therapy (TT) in a real-world setting
|
Atkins, M.B.
|
|
|
31 |
S7 |
p. S1446
|
artikel
|
| 100 |
19P Tumour microenvironment and radiomics landscape associated with survival and prediction of immunotherapy in patients with cancer
|
Zhang, W.
|
|
|
31 |
S7 |
p. S1423
|
artikel
|
| 101 |
15P Tumour PD-L1 expression and blood biomarkers of activity of adaptive immunity and tumour microenvironment in patients with solid tumours
|
Malkova, A.
|
|
|
31 |
S7 |
p. S1422
|
artikel
|
| 102 |
5P Uncovering the evolution of glioblastoma proteome landscape from primary to the recurrent stage for development of novel diagnostic and predictive biomarkers
|
Tatari, N.
|
|
|
31 |
S7 |
p. S1419
|
artikel
|
| 103 |
50P Update of systematic reviews and meta-analyses studying the association between antibiotic use and clinical outcomes of cancer patients treated with immune checkpoint inhibitors
|
Zalcman, G.
|
|
|
31 |
S7 |
p. S1436
|
artikel
|
| 104 |
RETRACTED: ORIENT-3: A randomized, open-label, phase III study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small cell lung cancer (sqNSCLC)
|
Shi, Y.
|
|
|
31 |
S7 |
p. S1428
|
artikel
|
| 105 |
Table of Contents
|
|
|
|
31 |
S7 |
p. viii
|
artikel
|
| 106 |
97TiP Identification of therapeutic targets in patients with squamous cell carcinoma of the head and neck who progress on or after anti-PD-(L)1 therapy: An IMMUcan sub-project
|
van der Elst, A.
|
|
|
31 |
S7 |
p. S1455-S1456
|
artikel
|
| 107 |
84TiP Neo-CheckRay: Radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer: A randomized phase II trial
|
De Caluwe, A.
|
|
|
31 |
S7 |
p. S1451
|
artikel
|
| 108 |
Title Page
|
|
|
|
31 |
S7 |
p. iv
|
artikel
|
Tijdschrift beschrijving